<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240329001059&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240329001059&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 29 Mar 2024 04:11:00 +0000</lastbuilddate>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction to: Prednisone administration in inflammatory cardiomyopathy: caveat for potentially adverse myocardial actions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547459/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae219. doi: 10.1093/eurheartj/ehae219. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547459/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547459</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae219>10.1093/eurheartj/ehae219</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547459</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Prednisone administration in inflammatory cardiomyopathy: caveat for potentially adverse myocardial actions</dc:title>
<dc:identifier>pmid:38547459</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae219</dc:identifier>
</item>
<item>
<title>Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547456/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae167. doi: 10.1093/eurheartj/ehae167. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547456/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547456</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae167>10.1093/eurheartj/ehae167</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547456</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly journal scan: a hard RAFTing to improve long-term survival in heart failure with severely reduced ejection fraction</dc:title>
<dc:identifier>pmid:38547456</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae167</dc:identifier>
</item>
<item>
<title>Sorbs2 Modulation of BK Channels in Arterial Myocytes: Implications for Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547252/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):872-874. doi: 10.1161/CIRCRESAHA.124.324241. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547252/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547252</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324241>10.1161/CIRCRESAHA.124.324241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547252</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>L Fernando Santana</dc:creator>
<dc:creator>Manuel F Navedo</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Sorbs2 Modulation of BK Channels in Arterial Myocytes: Implications for Diabetes</dc:title>
<dc:identifier>pmid:38547252</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324241</dc:identifier>
</item>
<item>
<title>Biological Pacemakers: Present and Future</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):837-841. doi: 10.1161/CIRCRESAHA.123.323180. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547251</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323180>10.1161/CIRCRESAHA.123.323180</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547251</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Thassio Mesquita</dc:creator>
<dc:creator>Rodrigo Miguel-Dos-Santos</dc:creator>
<dc:creator>Eugenio Cingolani</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Biological Pacemakers: Present and Future</dc:title>
<dc:identifier>pmid:38547251</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323180</dc:identifier>
</item>
<item>
<title>Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>The ECM (extracellular matrix) is a major component of the vascular microenvironment that modulates vascular homeostasis. ECM proteins include collagens, elastin, noncollagen glycoproteins, and proteoglycans/glycosaminoglycans. ECM proteins form complex matrix structures, such as the basal lamina and collagen and elastin fibers, through direct interactions or lysyl oxidase-mediated cross-linking. Moreover, ECM proteins directly interact with cell surface receptors or extracellular secreted...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):931-949. doi: 10.1161/CIRCRESAHA.123.324055. Epub 2024 Mar 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The ECM (extracellular matrix) is a major component of the vascular microenvironment that modulates vascular homeostasis. ECM proteins include collagens, elastin, noncollagen glycoproteins, and proteoglycans/glycosaminoglycans. ECM proteins form complex matrix structures, such as the basal lamina and collagen and elastin fibers, through direct interactions or lysyl oxidase-mediated cross-linking. Moreover, ECM proteins directly interact with cell surface receptors or extracellular secreted molecules, exerting matricellular and matricrine modulation, respectively. In addition, extracellular proteases degrade or cleave matrix proteins, thereby contributing to ECM turnover. These interactions constitute the ECM interactome network, which is essential for maintaining vascular homeostasis and preventing pathological vascular remodeling. The current review mainly focuses on endogenous matrix proteins in blood vessels and discusses the interaction of these matrix proteins with other ECM proteins, cell surface receptors, cytokines, complement and coagulation factors, and their potential roles in maintaining vascular homeostasis and preventing pathological remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547250</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324055>10.1161/CIRCRESAHA.123.324055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547250</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi Fu</dc:creator>
<dc:creator>Yuan Zhou</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Zhuofan Li</dc:creator>
<dc:creator>Wei Kong</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling</dc:title>
<dc:identifier>pmid:38547250</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324055</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547249/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):834-836. doi: 10.1161/RES.0000000000000667. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547249/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547249</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000667>10.1161/RES.0000000000000667</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547249</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38547249</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000667</dc:identifier>
</item>
<item>
<title>Untangling Complexity: Gut Microbiota, Metabolites, and Fiber Intake in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547248/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):855-857. doi: 10.1161/CIRCRESAHA.124.324333. Epub 2024 Mar 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547248/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547248</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324333>10.1161/CIRCRESAHA.124.324333</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547248</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Nathan T Greenberg</dc:creator>
<dc:creator>Vienna E Brunt</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Untangling Complexity: Gut Microbiota, Metabolites, and Fiber Intake in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38547248</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324333</dc:identifier>
</item>
<item>
<title>Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38547246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among United States Hispanics/Latinos, dietary fiber intake was associated with favorable profiles of gut microbiota and circulating metabolites for T2D. These findings advance our understanding of the role of gut microbiota and microbial metabolites in the relationship between diet and T2D.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar 29;134(7):842-854. doi: 10.1161/CIRCRESAHA.123.323634. Epub 2024 Mar 28.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Consistent evidence suggests diabetes-protective effects of dietary fiber intake. However, the underlying mechanisms, particularly the role of gut microbiota and host circulating metabolites, are not fully understood. We aimed to investigate gut microbiota and circulating metabolites associated with dietary fiber intake and their relationships with type 2 diabetes (T2D).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study included up to 11 394 participants from the HCHS/SOL (Hispanic Community Health Study/Study of Latinos). Diet was assessed with two 24-hour dietary recalls at baseline. We examined associations of dietary fiber intake with gut microbiome measured by shotgun metagenomics (350 species/85 genera and 1958 enzymes; n=2992 at visit 2), serum metabolome measured by untargeted metabolomics (624 metabolites; n=6198 at baseline), and associations between fiber-related gut bacteria and metabolites (n=804 at visit 2). We examined prospective associations of serum microbial-associated metabolites (n=3579 at baseline) with incident T2D over 6 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We identified multiple bacterial genera, species, and related enzymes associated with fiber intake. Several bacteria (eg, <i>Butyrivibrio</i>, <i>Faecalibacterium</i>) and enzymes involved in fiber degradation (eg, xylanase EC3.2.1.156) were positively associated with fiber intake, inversely associated with prevalent T2D, and favorably associated with T2D-related metabolic traits. We identified 159 metabolites associated with fiber intake, 47 of which were associated with incident T2D. We identified 18 of these 47 metabolites associated with the identified fiber-related bacteria, including several microbial metabolites (eg, indolepropionate and 3-phenylpropionate) inversely associated with the risk of T2D. Both <i>Butyrivibrio</i> and <i>Faecalibacterium</i> were associated with these favorable metabolites. The associations of fiber-related bacteria, especially <i>Faecalibacterium</i> and <i>Butyrivibrio</i>, with T2D were attenuated after further adjustment for these microbial metabolites.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among United States Hispanics/Latinos, dietary fiber intake was associated with favorable profiles of gut microbiota and circulating metabolites for T2D. These findings advance our understanding of the role of gut microbiota and microbial metabolites in the relationship between diet and T2D.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38547246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38547246</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323634>10.1161/CIRCRESAHA.123.323634</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38547246</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zheng Wang</dc:creator>
<dc:creator>Brandilyn A Peters</dc:creator>
<dc:creator>Bing Yu</dc:creator>
<dc:creator>Megan L Grove</dc:creator>
<dc:creator>Tao Wang</dc:creator>
<dc:creator>Xiaonan Xue</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Eric Boerwinkle</dc:creator>
<dc:creator>Gang Hu</dc:creator>
<dc:creator>Yasmin Mossavar-Rahmani</dc:creator>
<dc:creator>Carmen R Isasi</dc:creator>
<dc:creator>Rob Knight</dc:creator>
<dc:creator>Robert D Burk</dc:creator>
<dc:creator>Robert C Kaplan</dc:creator>
<dc:creator>Qibin Qi</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes</dc:title>
<dc:identifier>pmid:38547246</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323634</dc:identifier>
</item>
<item>
<title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae025. doi: 10.1093/eurheartj/ehae025. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38546417</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae025>10.1093/eurheartj/ehae025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546417</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Maria Grazia Bongiorni</dc:creator>
<dc:creator>Giulio Zucchelli</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Blood stream infection in defibrillator recipients: cardiac imaging for all patients or sometimes skillful neglect?</dc:title>
<dc:identifier>pmid:38546417</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae025</dc:identifier>
</item>
<item>
<title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae127. doi: 10.1093/eurheartj/ehae127. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Bloodstream infection (BSI) of any cause may lead to device infection in cardiac implantable electronic device (CIED) patients. Aiming for a better understanding of the diagnostic approach, treatment, and outcome, patients with an implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy and defibrillator (CRT-D) hospitalized with BSI were investigated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This is a single-centre, retrospective, cohort analysis including consecutive ICD/CRT-D patients implanted between 2012 and 2021. These patients were screened against a list of all hospitalized patients having positive blood cultures consistent with diagnosed infection in any department of a local public hospital.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The total cohort consisted of 515 patients. Over a median follow-up of 59 months (interquartile range 31-87 months), there were 47 BSI episodes in 36 patients. The majority of patients with BSI (92%) was admitted to non-cardiology units, and in 25 episodes (53%), no cardiac imaging was performed. Nearly all patients (85%) were treated with short-term antibiotics, whereas chronic antibiotic suppression therapy (n = 4) and system extraction (n = 3) were less frequent. Patients with BSI had a nearly seven-fold higher rate (hazard ratio 6.7, 95% confidence interval 3.9-11.2; P &lt; .001) of all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diagnostic workup of defibrillator patients with BSI admitted to a non-cardiology unit is often insufficient to characterize lead-related endocarditis. The high mortality rate in these patients with BSI may relate to underdiagnosis and consequently late/absence of system removal. Efforts to increase an interdisciplinary approach and greater use of cardiac imaging are necessary for timely diagnosis and adequate treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38546408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38546408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae127>10.1093/eurheartj/ehae127</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38546408</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Tardu Özkartal</dc:creator>
<dc:creator>Andrea Demarchi</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:creator>Damiano Pongan</dc:creator>
<dc:creator>Catherine Klersy</dc:creator>
<dc:creator>Maria Luce Caputo</dc:creator>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Enos Bernasconi</dc:creator>
<dc:creator>Valeria Gaia</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac implantable electronic devices and bloodstream infections: management and outcomes</dc:title>
<dc:identifier>pmid:38546408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae127</dc:identifier>
</item>
<item>
<title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 28. doi: 10.1161/CIR.0000000000001225. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Wearable biosensors (wearables) enable continual, noninvasive physiologic and behavioral monitoring at home for those with pediatric or congenital heart disease. Wearables allow patients to access their personal data and monitor their health. Despite substantial technologic advances in recent years, issues with hardware design, data analysis, and integration into the clinical workflow prevent wearables from reaching their potential in high-risk congenital heart disease populations. This science advisory reviews the use of wearables in patients with congenital heart disease, how to improve these technologies for clinicians and patients, and ethical and regulatory considerations. Challenges related to the use of wearables are common to every clinical setting, but specific topics for consideration in congenital heart disease are highlighted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38545775/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38545775</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001225>10.1161/CIR.0000000000001225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38545775</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Animesh Tandon</dc:creator>
<dc:creator>Jennifer N Avari Silva</dc:creator>
<dc:creator>Ami B Bhatt</dc:creator>
<dc:creator>Colin K Drummond</dc:creator>
<dc:creator>Allison C Hill</dc:creator>
<dc:creator>Amanda E Paluch</dc:creator>
<dc:creator>Sheradon Waits</dc:creator>
<dc:creator>Jenny E Zablah</dc:creator>
<dc:creator>Kevin C Harris</dc:creator>
<dc:creator>Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts); Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Advancing Wearable Biosensors for Congenital Heart Disease: Patient and Clinician Perspectives: A Science Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:38545775</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001225</dc:identifier>
</item>
<item>
<title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae158. doi: 10.1093/eurheartj/ehae158. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Built environment plays an important role in the development of cardiovascular disease. Tools to evaluate the built environment using machine vision and informatic approaches have been limited. This study aimed to investigate the association between machine vision-based built environment and prevalence of cardiometabolic disease in US cities.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This cross-sectional study used features extracted from Google Street View (GSV) images to measure the built environment and link them with prevalence of coronary heart disease (CHD). Convolutional neural networks, linear mixed-effects models, and activation maps were utilized to predict health outcomes and identify feature associations with CHD at the census tract level. The study obtained 0.53 million GSV images covering 789 census tracts in seven US cities (Cleveland, OH; Fremont, CA; Kansas City, MO; Detroit, MI; Bellevue, WA; Brownsville, TX; and Denver, CO).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Built environment features extracted from GSV using deep learning predicted 63% of the census tract variation in CHD prevalence. The addition of GSV features improved a model that only included census tract-level age, sex, race, income, and education or composite indices of social determinant of health. Activation maps from the features revealed a set of neighbourhood features represented by buildings and roads associated with CHD prevalence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this cross-sectional study, the prevalence of CHD was associated with built environment factors derived from GSV through deep learning analysis, independent of census tract demographics. Machine vision-enabled assessment of the built environment could potentially offer a more precise approach to identify at-risk neighbourhoods, thereby providing an efficient avenue to address and reduce cardiovascular health disparities in urban environments.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38544295</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae158>10.1093/eurheartj/ehae158</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544295</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Zhuo Chen</dc:creator>
<dc:creator>Jean-Eudes Dazard</dc:creator>
<dc:creator>Yassin Khalifa</dc:creator>
<dc:creator>Issam Motairek</dc:creator>
<dc:creator>Sadeer Al-Kindi</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-based assessment of built environment from Google Street View and coronary artery disease prevalence</dc:title>
<dc:identifier>pmid:38544295</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae158</dc:identifier>
</item>
<item>
<title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 28:ehae159. doi: 10.1093/eurheartj/ehae159. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38544282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38544282</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae159>10.1093/eurheartj/ehae159</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38544282</guid>
<pubDate>Thu, 28 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-03-28</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence-enhanced exposomics: novel insights into cardiovascular health</dc:title>
<dc:identifier>pmid:38544282</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae159</dc:identifier>
</item>
<item>
<title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):e129. doi: 10.1016/j.jacc.2024.01.032. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538207/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538207</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.032>10.1016/j.jacc.2024.01.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538207</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>R Scott Wright</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Anastasia Lesogor</dc:creator>
<dc:creator>Kausik K Ray</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Evaluation of the Inclisiran Safety in High-Risk Populations</dc:title>
<dc:identifier>pmid:38538207</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.032</dc:identifier>
</item>
<item>
<title>Evaluation of the Inclisiran Safety in High-Risk Populations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538206/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):e127. doi: 10.1016/j.jacc.2023.12.037. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538206/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538206</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.037>10.1016/j.jacc.2023.12.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538206</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Xin Jiang</dc:creator>
<dc:creator>Zhengjun Zhang</dc:creator>
<dc:creator>Hao Ding</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evaluation of the Inclisiran Safety in High-Risk Populations</dc:title>
<dc:identifier>pmid:38538206</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.037</dc:identifier>
</item>
<item>
<title>Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538205/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1253-1255. doi: 10.1016/j.jacc.2024.01.031. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538205/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538205</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.031>10.1016/j.jacc.2024.01.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538205</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Errol Moras</dc:creator>
<dc:creator>Kruti Gandhi</dc:creator>
<dc:creator>Anoop N Koshy</dc:creator>
<dc:creator>Kirtipal Bhatia</dc:creator>
<dc:creator>Chayakrit Krittanawong</dc:creator>
<dc:creator>Abel Casso Dominguez</dc:creator>
<dc:creator>Edgar Argulian</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mitral Transcatheter Edge-to-Edge Repair in Patients With Atrial Functional Mitral Regurgitation</dc:title>
<dc:identifier>pmid:38538205</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.031</dc:identifier>
</item>
<item>
<title>Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>Because signs of congestion are associated with adverse outcomes in patients with acute heart failure (AHF), attempts were made to decongest patients as much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical devices. Those interventions improved signs of congestion but failed to meaningfully improve patients' symptoms, improve quality of life, or reduce early readmissions or deaths. Recent studies have shown that implementation of guideline-directed...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1243-1252. doi: 10.1016/j.jacc.2024.01.029. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Because signs of congestion are associated with adverse outcomes in patients with acute heart failure (AHF), attempts were made to decongest patients as much as possible with diuretic agents (loop diuretic agents, thiazides, acetazolamide) or mechanical devices. Those interventions improved signs of congestion but failed to meaningfully improve patients' symptoms, improve quality of life, or reduce early readmissions or deaths. Recent studies have shown that implementation of guideline-directed medical therapies after an AHF admission led to both more decongestion and improved symptoms, quality of life, and outcomes. Therefore, for most patients with AHF whose symptoms and congestion can be controlled with loop diuretic agents, the main focus should be rapid guideline-directed medical therapy uptitration. Enhanced decongestion, ie, adding a second-line diuretic agent to a loop diuretic agent, should be reserved for those patients who do not respond to loop diuretic agents.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538204</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.029>10.1016/j.jacc.2024.01.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538204</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Gad Cotter</dc:creator>
<dc:creator>Beth Davison</dc:creator>
<dc:creator>Ovidiu Chioncel</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Enhanced Decongestive Therapy in Patients With Acute Heart Failure: JACC Review Topic of the Week</dc:title>
<dc:identifier>pmid:38538204</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.029</dc:identifier>
</item>
<item>
<title>Need for 'One-Stop-Shop' Heart-Brain-Placental Imaging in Fetal Congenital Heart Disease: Fetal Hemodynamics Portend Neurodevelopmental Outcome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538203/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1240-1242. doi: 10.1016/j.jacc.2024.02.022. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538203/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538203</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.022>10.1016/j.jacc.2024.02.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538203</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Ashok Panigrahy</dc:creator>
<dc:creator>Jodie K Votava-Smith</dc:creator>
<dc:creator>Daniel J Licht</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Need for 'One-Stop-Shop' Heart-Brain-Placental Imaging in Fetal Congenital Heart Disease: Fetal Hemodynamics Portend Neurodevelopmental Outcome</dc:title>
<dc:identifier>pmid:38538203</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.022</dc:identifier>
</item>
<item>
<title>Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients With Cyanotic Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538202/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among fetuses with cyanotic CHD, diminished fetal combined ventricular output is associated with mortality, whereas cerebral blood flow and oxygen delivery are associated with early cognitive, language, and motor development at 18 months of age. These results support the inclusion of fetal CMR to help identify patients at risk of adverse ND outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1225-1239. doi: 10.1016/j.jacc.2024.02.005. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Fetuses with cyanotic congenital heart disease (CHD) exhibit profound fetal circulatory disturbances that may affect early outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate the relationship between fetal hemodynamics and early survival and neurodevelopmental (ND) outcomes in patients with cyanotic CHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this longitudinal observational study, fetuses with cyanotic CHD underwent late gestational fetal cardiovascular magnetic resonance (CMR) to measure vessel blood flow and oxygen content. Superior vena cava (SVC) flow was used as a proxy for cerebral blood flow. Primary outcomes were 18-month mortality and Bayley Scales of Infant Development-III assessment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 144 fetuses with cyanotic CHD were assessed. By 18 months, 18 patients (12.5%) died. Early mortality was associated with reduced combined ventricular output (P = 0.01), descending aortic flow (P = 0.04), and umbilical vein flow (P = 0.03). Of the surviving patients, 71 had ND outcomes assessed. Cerebral oxygen delivery was the fetal hemodynamic variable most strongly associated with cognitive, language, and motor outcomes (P &lt; 0.05). Fetal SVC flow was also associated with cognitive, language, and motor outcomes (P &lt; 0.01), and it remained an independent predictor of cognitive (P = 0.002) and language (P = 0.04) outcomes after adjusting for diagnosis. Diminished SVC flow also performed better than other fetal CMR and echocardiographic predictors of cognitive ND delay (receiver-operating characteristic curve area: 0.85; SE 0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among fetuses with cyanotic CHD, diminished fetal combined ventricular output is associated with mortality, whereas cerebral blood flow and oxygen delivery are associated with early cognitive, language, and motor development at 18 months of age. These results support the inclusion of fetal CMR to help identify patients at risk of adverse ND outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538202/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538202</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.005>10.1016/j.jacc.2024.02.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538202</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Fu-Tsuen Lee</dc:creator>
<dc:creator>Liqun Sun</dc:creator>
<dc:creator>Joshua F P van Amerom</dc:creator>
<dc:creator>Sharon Portnoy</dc:creator>
<dc:creator>Davide Marini</dc:creator>
<dc:creator>Amandeep Saini</dc:creator>
<dc:creator>Natasha Milligan</dc:creator>
<dc:creator>Jessie Mei Lim</dc:creator>
<dc:creator>Brahmdeep Saini</dc:creator>
<dc:creator>Thiviya Selvanathan</dc:creator>
<dc:creator>Vanna Kazazian</dc:creator>
<dc:creator>Renee Sananes</dc:creator>
<dc:creator>Edgar Jaeggi</dc:creator>
<dc:creator>John C Kingdom</dc:creator>
<dc:creator>Christopher K Macgowan</dc:creator>
<dc:creator>Linh Ly</dc:creator>
<dc:creator>Vann Chau</dc:creator>
<dc:creator>Steven P Miller</dc:creator>
<dc:creator>Mike Seed</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fetal Hemodynamics, Early Survival, and Neurodevelopment in Patients With Cyanotic Congenital Heart Disease</dc:title>
<dc:identifier>pmid:38538202</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.005</dc:identifier>
</item>
<item>
<title>Paclitaxel-Mortality Risk Hypothesis Debunked: What We Learned and How It Will Change Future Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538201/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1222-1224. doi: 10.1016/j.jacc.2024.02.023. Epub 2024 Mar 25.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538201/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538201</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.023>10.1016/j.jacc.2024.02.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538201</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter A Schneider</dc:creator>
<dc:creator>Jeffrey W Olin</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Paclitaxel-Mortality Risk Hypothesis Debunked: What We Learned and How It Will Change Future Clinical Trials</dc:title>
<dc:identifier>pmid:38538201</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.023</dc:identifier>
</item>
<item>
<title>Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38538200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240329001059&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease. (The DETECT Project; NCT05254106).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 2;83(13):1207-1221. doi: 10.1016/j.jacc.2024.02.003. Epub 2024 Mar 25.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: According to a meta-analysis of randomized clinical trials, paclitaxel-coated devices (PCDs) for lower limb endovascular revascularization may be associated with increased risk of late mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to determine whether PCDs are associated with all-cause mortality in a real-world setting.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: DETECT is a nationwide, exhaustive retrospective cohort study using medico-administrative data from the French National Healthcare System representing >;99% of the population. The main selection criterion was the first procedure of interest: endovascular revascularization for lower limb peripheral artery disease involving ≥1 balloon and/or stent performed between October 1, 2011, and December 31, 2019. Patients with or without PCDs were compared for all-cause mortality until December 31, 2021.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 259,137 patients were analyzed, with 20,083 (7.7%) treated with ≥1 PCD. After a median follow-up of 4.1 years (Q1-Q3: 2.3-6.4 years), a total of 5,385 deaths/73,923 person-years (PY) (7.3/100 PY) and 109,844 deaths/1,060,513 PY (10.4/100 PY) were observed in the PCD and control groups, respectively. After adjustment for confounding factors, PCD treatment was associated with a lower risk of mortality in multivariable Cox analyses (HR: 0.86; 95% CI: 0.84-0.89; P &lt; 0.001). Similar results were observed using propensity score matching approaches based on either nearest-neighbor or exact matching.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a nationwide analysis based on large-scale real-world data, exposure to PCDs was not associated with a higher risk of mortality in patients undergoing endovascular revascularization for lower limb peripheral artery disease. (The DETECT Project; NCT05254106).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38538200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240329001059&v=2.18.0.post9+e462414">38538200</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.003>10.1016/j.jacc.2024.02.003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38538200</guid>
<pubDate>Wed, 27 Mar 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthieu Wargny</dc:creator>
<dc:creator>Christophe Leux</dc:creator>
<dc:creator>Gilles Chatellier</dc:creator>
<dc:creator>Sandrine Coudol</dc:creator>
<dc:creator>Pierre-Antoine Gourraud</dc:creator>
<dc:creator>Yann Gouëffic</dc:creator>
<dc:date>2024-03-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mortality in a Nationwide Practice-Based Cohort Receiving Paclitaxel-Coated Devices for Lower Limb Peripheral Artery Disease</dc:title>
<dc:identifier>pmid:38538200</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.003</dc:identifier>
</item>





























</channel>
</rss>